SCHEMBL10186258

SCHEMBL10186258

O=C(NCCNC(=O)N1CCC(C(F)(F)F)CC1)c1ccc(O[C@H]2CC[C@@H](C(=O)O)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HRH3 Q9Y5N1 4/20 0.43
EPHX2 P34913 5/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
FAAH O00519 1/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2J2 P51589 1/20 0.43
GAA P10253 1/20 0.43
OPRM1 P35372 2/20 0.42
OPRD1 P41143 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
DGAT1 O75907 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10185085 0.90 LMNA (0.50) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10186504 0.88 EPHX2 (0.52) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10186461 0.88 LMNA (0.52) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10185216 0.87 L3MBTL1 (0.51) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10185006 0.86 EPHX2 (0.56) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10185130 0.86 FAAH (0.46) L3MBTL1HRH3EPHX2FAAHDGAT1
SCHEMBL10185363 0.85 L3MBTL1 (0.50) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10185355 0.85 L3MBTL1 (0.52) L3MBTL1LMNAKDM4EHRH3EPHX2
SCHEMBL10184500 0.85 LMNA (0.46) L3MBTL1LMNAKDM4EHRH3MAPT
SCHEMBL10184515 0.85 EPHX2 (0.48) L3MBTL1LMNAKDM4EHRH3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 L3MBTL1 607/4885LMNA 2889/4885KDM4E 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.